A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Colorectal Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically or cytologically confirmed previously treated metastatic colorectal cancer with adenocarcinoma histology. 2) Participants with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression.

You may not be eligible for this study if the following are true:

  • 1) BRAF V600 mutant colorectal cancer. 2) Active brain metastases or leptomeningeal metastases. 3) Active, known or suspected autoimmune disease.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.